Usefulness of fecal calprotectin determination in pediatric intestinal diseases

Minerva Pediatrica

Volumn 68, Issue 6, 2016, Pages 478-486

  Rosso, Chiara ^a   Caviglia, Gian P ^a   Pellicano, Rinaldo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Colitis; Gastrointestinal diseases; Inflammatory bowel diseases; Pediatrics

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR 4;

ABDOMINAL PAIN; APOPTOSIS; CELL GROWTH; CELL SURVIVAL; CROHN DISEASE; ENTEROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIC COLITIS; FECES MICROFLORA; HUMAN; INFANTILE COLIC; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LYMPHOCYTIC COLITIS; NECROTIZING ENTEROCOLITIS; REVIEW; ULCERATIVE COLITIS; CHEMISTRY; CHILD; FECES; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; METABOLISM; PATHOLOGY;

BIOMARKERS; CHILD; FECES; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTESTINAL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX;

EID: 84994353640     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009;58:859-68.
2. Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H. Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994;35:669-74.
3. Fagerhol MK. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24:393-8.
4. Cuida M, Brun JG, Tynning T, Jonsson R. Calprotectin levels in oral fluids: the importance of collection site. Eur J Oral Sci 1995;103:8-10.
5. Holt J, Fagerhol MK, Dale I. Quantitation of a leukocyte protein (L1) in urine. Acta Paediatr Scand 1983;72:615-6.
6. Nisapakultorn K, Ross KF, Herzberg MC. Calprotectin expression inhibits bacterial binding to mucosal epithelial cells. Infect Immun 2001;69:3692-6.
7. Duman M, Gencpinar P, Bicmen M, Arslan N, Ozden O, Uzum O, et al. Fecal calprotectin: can be used to distinguish between bacterial and viral gastroenteritis in children? Am J Emerg Med 2015;33:1436-9.
8. Brophy MB, Hayden JA, Nolan EM. Calcium ion gradients modulate the zinc affinity and antibacterial activity of human calprotectin. J Am Chem Soc 2012;134:18089-100.
9. Steven MD, Thomas EK, Norie S, Marilyn EH, Subodh R, Wesley JM, et al. Molecular basis for manganese sequestration by calprotectin and roles in the innate immune response to invading bacterial pathogens. Proc Natl Acad Sci USA 2013;110:3841-6.
10. Striz I, Trebichavsky I. Calprotectin-A pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245-53.
11. Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol Pathol 2001;54:289-92.
12. Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18:756-62.
13. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008;14:32-9.
14. Maconi G. Overlapping gastrointestinal disorders in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2015;61:199-200.
15. Actis GC, Pellicano R, Tarallo S, Rosina F. Commonalities and differences between Crohn's disease and ulcerative colitis: the genetic clues to their interpretation. Inflamm Allergy Drug Targets 2011;10:447-54.
16. Lee JM, Steven TL, Tamarah K, Andrew SD, Adam J, Chee YO. Update of faecal markers of inflammation in children with cystic fibrosis. Mediat Inflamm 2012;2012:948367.
17. Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013;7:827-51.
18. Caviglia GP, Touscoz GA, Pellicano R, Astegiano M. Fecal calprotectin: a biomarker for intestinal inflammation. Inflamm Cell Sign 2015;2:e563.
19. Limburg PJ, Ahlquist DA, Sandborn WJ, Mahoney DW, Devens ME, Harrington JJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000;95:2831-7.
20. Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004;13:279-84.
21. Tibble JA, Igthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
22. Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, et al. Faecal calprotectin in the assessment of Crohn's disease activity. Qjm 2005;98:435-41.
23. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22.
24. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005;54:364-8.
25. Caviglia GP, Pantaleoni S, Touscoz GA, Adriani A, Rosso C, Smedile A, et al. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol 2014;49:1419-24.
26. Furfaro F, Bezzio C, Maconi G. Protein-losing enteropathy in inflammatory bowel diseases. Minerva Gastroenterol Dietol. 2015;61:261-5.
27. Ardesia M, Villanacci V, Fries W. The aged gut in inflammatory bowel diseases. Minerva Gastroenterol Dietol 2015;61:235-47.
28. Benchimol EI, Mack DR, Nguyen GC, Snapper SB, Li W, Mojaverian N, et al. Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease Gastroenterology 2014;147:803-13.
29. Lovasz BD, Lakatos L, Horvath A, Pandur T, Erdelyi Z, Balogh M, et al. Incidence rates and disease course of pediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011. Dig Liver Dis 2014;46:405-11.
30. Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr 2013;57:29-34.
31. Hildebrend H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003;52:1432-4.
32. Lapidus A. Crohn's disease in Stockholm County during 1990-2001: an epidemiological update. World J Gastroenterol 2006;12:75-81.
33. Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut 1996;39:690-7.
34. Jussila A, Virta LJ, Salomaa V, Maki J, Jula A, Farkkila MA. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. J Crohn Colitis 2013;7:e256-e262.
35. Nerich V, Jantchou P, Boutron-Ruault MC, Monnet E, Weill A, Vanbockstael V, et al. Low exposure to sunlight is a risk factor for Crohn's disease. Aliment Pharmacol Ther 2011;33:940-5.
36. Hugot JP, Alberti C, Berrebi D, Bingen E, Cézard JP. Crohn's disease: the cold chain hypothesis. Lancet 2003;13:2012-5.
37. Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am J Gastroenterol 2006;101:993-1002.
38. Koloski NA, Bret L, Radford-Smith G. Hygiene hypothesis in inflammatory bowel disease: a critical review of the literature. World J Gastroenterol 2008;14:165-73.
39. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003;88:995-1000.
40. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr 2002;34:323-324.
41. Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert-Jacquin C, Barbot L, et al. High faecal calprotectin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed 2004;89:F353-5.
42. Olafsdottir E, Aksnes L, Fluge G, Berstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr 2002;91:45-50.
43. Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003;37:468-72.
44. Oord T, Hornung N. Fecal calprotectin in healthy children. Scand J Clin Lab Invest 2014;74(3):254-8.
45. Hestvik E, Tumwine JK, Tylleskar T, Grahnquist L, Ndeezi G, Kaddu-Mulindwa DH, et al. Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based survey. BMC Pediatr 2011;11:9.
46. Berni Canani R, Rapacciuolo L, Romano MT, Tanturri de Horatio L, Terrin G, Manguso F, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004;36:467-70.
47. Li F, Ma J, Geng S, Wang J, Liu J, Zhang J, Sheng X. Fecal calprotectin concentrations in healthy children aged 1-18 months. PLoS One 2015;10:e0119574.
48. Czub E, Nowak JK, Szaflarska-Poplawska A, Grzybowska-Chlebowczyk U, Landowski P, Moczko J, et al. Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity. Acta Biochim Pol 2014;61:99-102.
49. Komraus M, Wos H, Wiecek S, Kajor M, Grzybowska-Chlebowczyk U. Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediators Inflamm 2012;2012:608249.
50. Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology 2010;97:299-304.
51. Li F, Ma J, Geng S, Wang J, Ren F, Sheng X. Comparison of the different kinds of feeding on the level of fecal calprotectin. Comparison of the different kinds of feeding on the level of fecal calprotectin. Early Hum Dev 2014;90:471-5.
52. Dorosko SM, Mackenzie T, Connor RI. Fecal calprotectin concentrations are higher in exclusively breastfed in fants compared to those who are mixed-fed. Breastfeed Med 2008;3:117-9.
53. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6.
54. Rubio CA, Orrego A, Nesi G, Finkel Y. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol 2007;60:1268-72.
55. Buderus S, Scholz D, Behrens R, Classen M, De Laffolie J, Keller KM, et al. Inflammatory bowel disease in pediatric patients: characteristics of newly diagnosed patients from the CEDATACEDATACEDATA-GPGE Registry. Dtsch Arztebl Int 2015;112:121-7.
56. Zali H, Marashi SA, Rezaei-Tavirani M, Toossi P, Rahmati-Roodsari M, Shokrgozar MA. On the mechanism of apoptosis-inducing activity of human calprotectin: Zinc sequestration, induction of a signaling pathway, or something else? Med Hypotheses 2007;68:1012-5.
57. Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology 2004;126:1550-60.
58. Roszak D, Galecka M, Cichy W, Szachta P. Determination of faecal inflammatory marker concentration as noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases. Adv Med Sci 2015;60:246-52.
59. Kohlo KL, Turner D, Veerman-Wauters G, Sladek M, de Ridder L, Shaoul R, et al. Rapid test for fecal calprotectin levels in children with Crohn disease. J Pediatric Gastroenterol Nutr 2012;55:436-9.
60. Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol 2010;45:872-7.
61. Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy 2009;110:598-602.
62. Quail MA, Russell RK, Van Limbergen JE, Rogers P, Drummond HE, Wilson DC, et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009;15:756-9.
63. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem 2003;49:861-7.
64. Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14-22.
65. Sipponen T, Karkkainen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008;28:1221-9.
66. Sipponen T, Savilahti E, Kohlo KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-6.
67. Wake M, Morton-Allen E, Poulakis Z, Hiscock H, Gallagher S, Oberklaid F. Prevalence, stability, and outcomes of cry-fuss and sleep problems in the first 2 years of life: prospective community-based study. Pediatrics 2006;117:836-42.
68. Wessel MA, Cobb JC, Jackson EB, Harris GS, Detwiler AC. Paroxysmal fussing in infancy, sometimes called "colic." Pediatrics 1954;14:421-34.
69. McMahon C, Barnett B, Kowalenko N, Tennant C, Don N. Postnatal depression, anxiety and unsettled infant behaviour. Aust N Z J Psychiatry 2001;35:581-8.
70. Howard CR, Lanphear N, Lanphear BP, Eberly S, Lawrence RA. Parental responses to infant crying and colic: the effect on breastfeeding duration. Breastfeed Med 2006;1:146-55.
71. Rhoads JM, Fatheree NY, Norori J, Liu Y, Lucke JF, Tyson JE ,et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009;155:823-8.
72. Kapel N, Roman C, Caldari D, Sieprath F, Canioni D, Khalfoun Y, et al. Fecal tumor necrosis factor-A and calprotectin as differential diagnostic markers for severe diarrhea of small infants. J Pediatr Gastroenterol Nutr 2005;41:396-400.
73. Ruemmele FM, Brousse n, Goulet O. Autoimmune enteropathy: molecular concepts. Curr Opin Gastroenterol 2004;20:587-91.
74. Goulet O, Kedinger M, Brousse N, Cuenod B, Colomb V, Patey N, et al. Intractable diarrhea of infancy with epithelial and basement membrane abnormalities. J Pediatr 1995;127:212-9.
75. Walker-Smith JA. Intractable diarrhea in infancy: a continuing challenge for the pediatric gastroenterologist. Acta Pediatr 1994;83:6-9.
76. Yoon JM, Park JY, Ko KO, Lim JW, Cheon EJ, Kim HJ. Fecal calprotectin concentration in neonatal necrotizing enterocolitis. Korean J Pediatr 2014;57:351-6.
77. Thuijls G, Derikx JP, van Wijck K, Zimmermann LJ, Degraeuwe PL, Mulder TL, et al. Non-invasive markers for early diagnosis and determination of the severity of necrotizing enterocolitis. Ann Surg 2010;251:1174-80.
78. Carrol D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotizing enterocolitis. Lancet 2003;361:310-1.
79. Selimoglu MA, Temel I, Yildirim C, Ozyalin F, Aktas M, Harabiber H. The role of fecal calprotectin and lactoferrin in the diagnosis of necrotizing enterocolitis. Pediatric Clin Care Med 2011;13:452-4.
80. Francino MP. Early development of the gut microbiota and immune health. Pathogens 2014;24:769-90.
81. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-Associated I2 sequence and T-cell superantigen. Infect Immun 2002;70:6567-75.
82. Catanzaro R, Anzalone M, Calabrese F, Milazzo M, Capuana M, Italia A, et al. The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med 2015;57:127-43.
83. Iltanen S, Tervo L, Halttunen T, Wei B, Braun J, Rantala I, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis 2006;12:389-94.
84. Ashorn S, Honkanen T, Kolho KL, Ashorn M, Välineva T, Wei B, et al. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis 2009;15:199-205.
85. Kolho KL, Korpela K, Jaakkola T, Pichai MVAVA, Zoetendal EG, Solonen A, et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol 2015;110:921-30.
86. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;1:CD000542.
87. Actis GC, Pellicano R, Rizzetto M, Ayoubi M, Leone N, Tappero G, et al. Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol 2009;15:1420-6.
88. Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4:744-53.
89. Misra SM. Integrative therapies and pediatric inflammatory bowel disease: the current evidence. Children 2014;1:149-65.
90. De Greef E, Vandenplas Y, Hauser B, Devreker T, Veereman G. The use of probiotics in IBD and IBS. Minerva Pediatr 2014;66:491-500.
91. Maruotti N, D'Onofrio F, Neve A, Santoro N, Corrado A, Cantatore FP. Anti-TNF-A and risk of infections: the experience in one center. Panminerva Med 2014;56:31-4.
92. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johannas J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.